Intravesical BCG, induction and maintenance
Checked 2026-09-09
High-risk non-muscle-invasive bladder cancer after complete TURBT
One cycle
weekly × 6 · about 6 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
BCG Live bacterial immunotherapy (intravesical) | one full-dose vial (reduced dose during shortages) | Intravesical | D1 | held in the bladder for 2 hours |
Cycles
6 weekly inductions, then 3 weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months
7-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Products
Source
SWOG 8507 maintenance schedule; NCCN Bladder Cancer
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Gemcitabine + cisplatin
Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer
every 21 days × 8
Sacituzumab govitecan
Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies
every 21 days
Dose-dense MVAC
Muscle-invasive bladder cancer, cisplatin-eligible, before cystectomy
every 14 days × 3-4
Enfortumab vedotin + pembrolizumab
Locally advanced or metastatic urothelial cancer, first line, regardless of cisplatin eligibility
every 21 days